Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateDec 20, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, financials

TL;DR

GALECTIN THERAPEUTICS INC. filed an 8-K on 12/20/2024. Standard corporate update.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.

Why It Matters

This filing provides an update on Galectin Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine corporate filing (8-K) that does not appear to contain significant new material events or financial disclosures beyond standard reporting requirements.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves to report 'Other Events' and 'Financial Statements and Exhibits' as of December 20, 2024.

When was Galectin Therapeutics Inc. previously known by another name?

Galectin Therapeutics Inc. was formerly known as PRO PHARMACEUTICALS INC, with a date of name change on June 12, 2001.

Where is Galectin Therapeutics Inc. headquartered?

The company's principal executive office is located at 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240, NORCROSS, GA 30071.

In which U.S. state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

What is the SIC code for Galectin Therapeutics Inc.?

The Standard Industrial Classification (SIC) code for Galectin Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 415 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-12-20 07:50:19

Key Financial Figures

Filing Documents

01

Item 8.01 Other Items. On December 20, 2024 , Galectin Therapeutics Inc. (the "Company) issued the press release attached hereto as Exhibit 99.1, and incorporated herein by reference. SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated December 20, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: December 20, 2024 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing